Connect with us

Fertility

The future of family: unveiling 45 cutting-edge advancements in IVF

By FinDBest IVF 

Published

on

The past couple of years have witnessed exciting advancements in the IVF/ART space, driven by cutting-edge technologies and a relentless pursuit of improving fertility outcomes. Here, FinDBest IVF offers a glimpse into some notable breakthroughs.

1. EMBRYOSCOPE (VITROLIFE) – iDAScore

  • Area: Artificial Intelligence (AI) in Embryo Selection
  • Description: Time-lapse imaging AI platform analysing embryo development for improved selection.
  • Impact: Predicts implantation potential, increasing pregnancy rates and reducing miscarriages.
  • URL: Vitrolife iDAScore

2. EXAMEN – SpermComet

  • Area: Non-invasive Sperm Selection
  • Description: DNA fragmentation assay for improved sperm selection.
  • Impact: Identifies sperm with minimal DNA damage, potentially increasing fertilisation and implantation rates.
  • URL: Examen SpermComet

3. EXCELLENT SCIENCE (Cherry Biotech) – MicroFSMA

  • Area: Microfluidics-based Sperm Analysis
  • Description: Automated method for semen analysis and quality sperm isolation.
  • Impact: Improves detection of male infertility and quality sperm isolation.
  • URL: MicroFSMA

4. OVERTURE LIFE – DaVitri, m|z, and ICSI.A

  • Area: Automation of Full ART Cycle
  • Description: Automated IVF process technologies to enhance consistency and affordability.
  • Impact: Reduces variability in outcomes and makes IVF more affordable.
  • URL: Overture Life

5. IVF 2.0 – SiD

  • Area: Computer-enabled Sperm Quality Tracker
  • Description: Computer vision-based sperm selection tool.
  • Impact: Analyses sperm motility more accurately than the human eye.
  • URL: IVF 2.0 SiD

6. IVF 2.0 – ERICA

  • Area: AI and Machine Learning for Embryo Selection
  • Description: Prioritises euploid embryos using AI without sampling or biopsy.
  • Impact: Enhances embryo selection for higher success rates.
  • URL: IVF 2.0 ERICA

7. TMRW LifeSciences – CryoRobot Select

  • Area: Automation of Tracking, Monitoring, and Storing of Frozen Embryos
  • Description: AI-integrated platform for tracking and storing frozen eggs and embryos.
  • Impact: Improves clinical outcomes and optimises treatment costs.
  • URL: TMRW CryoRobot Select

8. LIFE WHISPERER – Life Whisperer Genetics (LWG)

  • Area: AI-powered Euploid Pre-screening of Embryos
  • Description: AI evaluation of genetic normality in embryos.
  • Impact: Non-invasive pre-screening of embryos for genetic normality.
  • URL: Life Whisperer Genetics

9. LIFE WHISPERER – Life Whisperer Viability (LWV)

  • Area: AI-powered Embryo Selection
  • Description: AI evaluation of embryo viability for clinical pregnancy.
  • Impact: Enhances embryo selection for better pregnancy outcomes.
  • URL: Life Whisperer Viability

10. INITO – Inito

  • Area: Point-of-Care Fertility Testing
  • Description: Home-based hormone testing kit for fertility assessment.
  • Impact: Provides affordable and convenient fertility screening.
  • URL: Inito

11. Cooper Surgical Fertility Companies – RI Witness ART Management System

  • Area: Witness System for Monitoring ART Cycles
  • Description: Automated control system for monitoring sample and embryo handling.
  • Impact: Standardises the environment and minimises human error.
  • URL: RI Witness

12. HAMILTON THORNE, MICROPTIC – CASA (Computer-Assisted Sperm Analysis), SCA (Sperm Class Analyzer)

  • Area: Advanced Sperm Motility Analysis
  • Description: Enhanced motility and morphology assessment systems.
  • Impact: Provides detailed sperm quality data for better selection.
  • URL: Hamilton-Thorne CASA
  • URL: SCA

13. AVA WOMEN – The Ava Bracelet

  • Area: Wearables
  • Description: Predicts optimal implantation window through cervical secretion analysis.
  • Impact: Identifies the most receptive time for embryo transfer.
  • URL: Ava Women

14. NATERA – Panorama™ Test

  • Area: Non-invasive Preimplantation Genetic Testing (PGT)
  • Description: NIPT-based analysis of foetal DNA for genetic abnormalities.
  • Impact: Safer and less invasive option for PGT.
  • URL: Natera Panorama

15. CONCEPTION BIO – Invitro Gametogenesis (IVG)

  • Area: Human Eggs from Stem Cells
  • Description: Generates eggs from induced pluripotent stem cells.
  • Impact: Potential breakthrough in fertility preservation.
  • URL: Conception Bio

16. KITAZATO – Soft Microrobot

  • Area: Microrobot-guided Embryo Transfer
  • Description: Controls the implantation position during embryo transfer.
  • Impact: Increases pregnancy rates and prevents ectopic pregnancy.
  • URL: Kitazato Microrobot

17. OURA – Oura Ring

  • Area: Wearable Health and Fertility Trackers
  • Description: Tracks biometric data relevant to fertility cycles.
  • Impact: Provides personalised insights into menstrual cycles and ovulation windows.
  • URL: Oura Ring

18. FERTILIS – Micro Devices for IVF Techniques

  • Area: General Automation of ART Process
  • Description: Micro medical devices for enhancing IVF treatment quality.
  • Impact: Improves oocyte retrieval, ICSI performance, and more.
  • URL: Fertilis

19. EMBL-EBI – AlphaFold DB

  • Area: AI-powered Sperm Morphology Analysis
  • Description: AI-based protein structure prediction for sperm morphology assessment.
  • Impact: Offers high-resolution analysis of sperm structure.
  • URL: AlphaFold

20. OVAREPRED (Pekin University Third Hospital) – OvaRePred

  • Area: Online Model for Ovarian Reserve Assessment
  • Description: Predicts the quantity of potential female eggs suitable for fertilisation.
  • Impact: Aids in treatment planning and optimising outcomes.
  • URL: OvaRePred

21. IGENOMIX (VITROLIFE) – WES

  • Area: IVF Genomics
  • Description: Whole exome sequencing for analysing gene coding sequences.
  • Impact: Cost-effective technique for genetic analysis.
  • URL: Igenomix WES

22. VISCOFAN, IT3D GROUP, TISSUELABS, ADVANCED SOLUTIONS

  • Area: 2D and 3D Printing of Biomaterials with Applications in IVF/ART
  • Description: Technologies for developing biomaterials using 2D and 3D printing.
  • Impact: Enhances the development and application of biomaterials in IVF/ART.
  • URL: Viscofan BioengineeringAdvanced SolutionsTissueLabsIT3D Group

23. FERTIL IBÉRICA – SpermVD

  • Area: Next-Generation Sperm Cryopreservation Techniques
  • Description: Vitrification process for improved sperm survival and motility.
  • Impact: Offers potential for longer sperm storage and improved fertilisation rates.
  • URL: Fertil Ibérica SpermVD

24. FLUIGENT – Microfluidics for Cell Biology

  • Area: Microfluidics for Cell Analysis
  • Description: Cell biology is crucial for medical innovation. Fluigent’s microfluidics technology integrates precise fluid flow control with microscopy, creating automated platforms for cell growth in physiologically relevant environments. This minimises error manipulation by automating fluid delivery at controlled rates.
  • Impact: Enhances accuracy and efficiency in cell biology experiments, facilitating better understanding and treatment of diseases.
  • URL: FLUIGENT – Microfluidics for Cell Biology

25. MICRONIT – Organ-on-a-Chip (OOC)

  • Area: Organ-on-a-Tube Microdevices
  • Description: Organ-on-a-chip devices simulate biological systems for in-vitro drug testing. Cells are cultured on membranes with separately controllable fluid flows, leading to more accurate biological representations than traditional methods. These resealable OOC flow cells allow cell seeding through standard protocols.
  • Impact: Provides more precise drug testing results, enhancing the drug development process.
  • URL: MICRONIT – Organ-on-a-Chip

26. ONI, BRUKER, WASATCH PHOTONICS, MALVERN PANALYTICAL, SPECTRA SOLUTIONS – Ultrasound-Guided TESA

  • Area: Non-invasive Testicular Sperm Extraction (TESA) with Ultrasound Guidance
  • Description: This technology offers a minimally invasive alternative to traditional sperm retrieval methods, using multiphoton microscopy, Raman spectroscopy, and optical coherence tomography for better visualisation and retrieval of sperm.
  • Impact: Potentially less painful and more efficient sperm retrieval method, improving patient comfort and outcomes.
  • URL: ONIBrukerWasatch PhotonicsMalvern Panalytical

27. MIM FERTILITY – FolliScan

  • Area: AI-powered Follicle Tracking and Ovulation Prediction
  • Description: AI software that analyses transvaginal ultrasound images to identify and measure follicles with high precision.
  • Impact: Improves accuracy in tracking ovulation, enhancing the chances of successful fertilisation.
  • URL: MIM FERTILITY – FolliScan

28. BERRY GENOMICS – NIPT-Based Analysis

  • Area: Non-invasive Prenatal Screening for Multiple Genetic Diseases
  • Description: Advanced NIPT technology that screens foetal DNA for a wide range of genetic abnormalities, beyond traditional panels.
  • Impact: Provides comprehensive prenatal genetic screening, leading to early detection and better management of genetic conditions.
  • URL: BERRY GENOMICS

29. Fairtility – CHLOE™

  • Area: Transparency in AI
  • Description: CHLOE™ is a transparent AI-based decision support tool that provides visibility into clinical and laboratory data to help improve IVF outcomes.
  • Impact: Enhances IVF success rates by offering detailed insights and data transparency to clinicians and prospective parents.

URL: Fairtility – CHLOE™30. ARWorks and The IVF Company – IVF Sim Pro

  • Area: Educational Tools with Virtual Reality (VR)
  • Description: VR software designed for technical training in ICSI and embryo biopsy, aimed at professionals, universities, and clinics.
  • Impact: Improves technical skills and training efficiency in IVF procedures through immersive virtual reality.
  • URL: IVF Sim Pro

31. Eggschain – Eggschain

  • Area: Blockchain Technology for IVF Patient Data
  • Description: Blockchain-integrated system for genomics, medical records, and biospecimen tracking, enabling patients to have greater control over their healthcare data.
  • Impact: Enhances data security and patient empowerment in managing healthcare information.
  • URL: Eggschain

32. Ovogene – Ovogene

  • Area: AI-Driven Donor Bank
  • Description: An international egg donor bank offering Genetically Certified Oocyte® technology, providing oocyte NGS screening and 100% euploid oocytes.
  • Impact: Increases success rates and reduces the need for multiple IVF attempts by ensuring high-quality oocytes.
  • URL: Ovogene

33. IVF-assistants.com – Skillsets

  • Area: AI-Driven Digital Assistants for Fertility Clinics
  • Description: Provides personalised access to information about ART and IVF services, helping patients understand their options and book consultations.
  • Impact: Enhances patient engagement and trust, improving consultation bookings and clinic-patient communication.
  • URL: IVF-assistants.com

34. inviTRA – Eeva Test

  • Area: Genomics for Optimal Embryo Selection
  • Description: Eeva test predicts which embryos have the greatest developmental potential using a time-lapse system attached to the incubator.
  • Impact: Improves embryo selection for transfer, enhancing the success rates of assisted reproduction treatments.
  • URL: inviTRA – Eeva Test

35. Lumiris – Metaphor™

  • Area: Embryo selection with metabolism data.
  • Description: Using metabolic imaging with AI-hyperspectral microscopy, the metabolic stress of embryos is assessed to determine its quality.
  • Impact: Improve selection of optimal embryos and therefore transfer success and fertilziation ratios.
  • URL:IBEC-Metaphor

36. Clue – Clue Birth Control, Clue Conceive

  • Area: Self-Managed Patient Care Using Smartphones (mHealth)
  • Description: App-based system for monitoring menstrual periods, ovulation, and PMS, offering numerous educational resources.
  • Impact: Empowers female patients to manage their reproductive health effectively using smartphone technology.
  • URL: Clue

37. ViOHealthTech – OvuSense OvuFirst, OvuSense OvuCore, and OvuSense Pro

  • Area: App-Based Patient Health Monitoring
  • Description: An app-based platform that helps screen for common health issues related to reproductive health, including ovulation tracking and fertility monitoring.
  • Impact: Provides comprehensive health monitoring, improving fertility tracking and assisting in managing reproductive health.
  • URL: ViOHealthTech

38. HERA Biotech – MetriDx

  • Area: Non-Surgical (Non-Invasive) Diagnostic Test for Endometriosis
  • Description: The world’s first non-surgical test for definitive diagnosis and staging of endometriosis.
  • Impact: Offers a less invasive and more accessible option for diagnosing and managing endometriosis.
  • URL: HERA Biotech

39. Labcorp – Preeclampsia Test

  • Area: Blood-based Screening Test
  • Description: The first screening test for assessing preeclampsia risk in the first trimester of pregnancy.
  • Impact: Enables early detection and management of preeclampsia, potentially improving maternal and fetal outcomes.
  • URL: Labcorp

40. EVOLUTIVE MEDICA – BreastDS, MiniPc Koios Medical, InferScholar, Airs Medical

  • Area: AI for Medical Image Analysis (Rx)
  • Description: AI-driven analysis and diagnostic technology for early and precise cancer detection.
  • Impact: Enhances accuracy and efficiency in cancer diagnostics, improving early detection and treatment outcomes.
  • URL: EVOLUTIVE MEDICA

41. Rhea – RheaLabs (including recently acquired Embryonics for AI-Driven Diagnostics)

  • Area: Technology Integration for Improved Patient Experience
  • Description: Integrated approach to patient engagement using AI and machine learning, enhancing clinic workflow and patient case management.
  • Impact: Provides a more seamless and meaningful patient experience, improving care quality and operational efficiency.
  • URL: Rhea – RheaLabs

42. AIVF – EMA Platform, ART Compass by AIVF

  • Area: AI Technology for Improved IVF Cycle Success and Management
  • Description: AI-powered IVF solutions for clinics, labs, and patients, including embryo evaluation, patient communication, and analytical tools.
  • Impact: Increases the certainty of successful IVF cycles by enhancing evaluation and communication processes.
  • URL: AIVF

43. Nilotech – Nilochecker

  • Area: State-of-the-Art Lab Equipment Calibration
  • Description: All-in-one reference instrument for controlling and calibrating critical laboratory equipment, such as incubators and warming systems.
  • Impact: Ensures accurate calibration and control, improving laboratory efficiency and reliability.
  • URL: Nilotech – Nilochecker

44. IBM and Ovum Health – IBM Watsonx Assistant

  • Area: Chatbot Assistant for Patient Communication and Management
  • Description: Custom AI applications for managing data sources and accelerating AI workflows, designed for enhanced patient communication and management in fertility clinics.
  • Impact: Streamlines patient interaction and clinic management, improving overall efficiency and patient satisfaction.
  • URL: IBM Watsonx

45. Spring Molecular Diagnostics – IVFinfo.AI

  • Area: ChatGPT-Like Site for IVF/ART Questions
  • Description: Multilingual website featuring an AI chatbot that answers questions about assisted reproduction (ART) and fertility.
  • Impact: Provides accessible and reliable information to patients, enhancing their understanding and decision-making in fertility treatments.
  • URL: AI

Pioneering frontiers in reproductive medicine

As the field of reproductive medicine continues to evolve, several pioneering areas of research are emerging. These cutting-edge advancements have the potential to revolutionise infertility treatments and offer new hope to individuals and couples facing reproductive challenges. Below, we highlight some of the most promising developments currently under investigation:

  • Mitochondrial Replacement Therapy: This experimental technique aims to prevent the transmission of mitochondrial diseases by replacing the mother’s mitochondria in the egg with healthy ones from a donor.
  • Artificial Womb Development: Artificial womb technology is under exploration for potential use in certain cases of infertility or high-risk pregnancies.
  • In Vitro Gametogenesis (IVG): Researchers are exploring ways to create sperm and egg cells from stem cells, which could offer new possibilities for infertile individuals and couples.
  • Nanotechnology in Reproductive Medicine: Nanotechnology holds promise in enhancing drug delivery systems, improving embryo culture conditions, and developing novel diagnostic tools for infertility.
  • 3D Bioprinting of Reproductive Tissues: Researchers are exploring the use of 3D bioprinting technology to create reproductive tissues, such as ovaries and uterine scaffolds, for transplantation or in vitro study, offering potential solutions for fertility preservation and restoration.
  • Non-Invasive Embryo Assessment Techniques: Non-invasive imaging modalities, such as optical coherence tomography (OCT) and time-lapse microscopy, are being explored for real-time monitoring and assessment of embryo development within the incubator, reducing the need for invasive embryo biopsy procedures.

These innovative approaches represent the forefront of reproductive research, promising to expand the possibilities of assisted reproduction and improve outcomes for patients worldwide.

The future is now: partnering with FinDBest IVF to realise your vision

The advancements outlined in this article paint a hopeful picture for the future of IVF/ART. While some technologies are still under development, many are already being implemented or can be brought to market faster through the right partnerships. This is where FinDBest IVF steps in.

FinDBest IVF: your partner for global expansion and innovation in IVF/ART

FinDBest IVF goes beyond connecting you with distributors; we’re your gateway to a world of possibilities. Our platform curates a network of service providers specializing in:

  • Market expansion services: Leverage market research firms to identify regions with the highest demand for your innovations.
  • Clinical trial management: Partner with experienced firms to navigate regulatory hurdles and conduct successful trials with leading fertility clinics.
  • Marketing and communication experts: Craft targeted campaigns that resonate with fertility clinics and healthcare professionals, ensuring your technology reaches the right audience.
The benefits of a comprehensive approach

Partnering with FinDBest IVF offers numerous advantages:

  • Faster time to market: Identify the right partners and navigate market complexities with greater efficiency.
  • Enhanced innovation: Collaborate with leading research institutions to bring groundbreaking technologies to market faster.
  • Streamlined communication: Connect with fertility clinics seeking solutions and build lasting relationships with key stakeholders.
FinDBest IVF: your partner in progress

The future of IVF/ART is bright. FinDBest IVF empowers you to foster innovation, build strong partnerships, and ensure your life-changing technologies reach the patients who need them most.

Join us and unlock the full potential of your IVF/ART solutions on a global scale. Let’s revolutionise the path to parenthood, together.

Entrepreneur

Kindbody unveils next-gen fertility platform

Published

on

Kindbody has launched a fertility platform integrating AI with clinical care and patient support for employers and health plans.

The platform will enter a pilot with select Kindbody employer clients in 2026, covering over three million lives, ahead of wider availability in 2027.

Building on the company’s clinical model, the platform aims to improve outcomes and cost efficiency across family-building journeys. It connects Kindbody-owned clinics, partner clinics and an integrated clinical app.

The app offers virtual care across conception, pregnancy and reproductive health, extending through the menopause transition.

Launch features include updates in medication management, third-party reproduction, adoption, pregnancy, men’s health and global programme design.

David Stern, chief executive of Kindbody, said: “With our next-generation fertility platform, Kindbody is redefining what comprehensive, intelligent and affordable family-building care looks like for employers, health plans and patients.

“By unifying best-in-class clinical care, AI-driven intelligence and whole-person support, we are making it easier and more cost-effective for more people to build the families they envision.”

Kindbody has expanded access via its national network of IVF centres, including IVIRMA, Inception Fertility and Ivy Fertility.

A new Fertility Medication Portal is designed to streamline authorisations so medicines can be dispensed on time, giving patients visibility from prescription to coverage, pharmacy fulfilment and delivery tracking.

Through KindMan, men’s health education, digital resources and integrated clinical care are expanding, including hormone management programmes.

Services cover andropause (age-related testosterone decline), erectile dysfunction, low testosterone and other male reproductive conditions.

Specialist fertility care includes semen analysis, diagnostic testing, male hormone panels, genetic testing, surgical sperm extraction and sperm cryopreservation.

Launching in the second quarter, a pregnancy support app will act as a digital companion for expecting and new parents, with resources, interactive tools and clinical assessments to identify social drivers of health and mental health needs during pregnancy and beyond.

Kindbody’s physician-led menopause programme provides consultations with board-certified obstetricians and gynaecologists to diagnose, treat and manage menopausal symptoms, including hormone replacement therapy where appropriate, with support from nutritionists, mental health therapists and pelvic floor specialists.

AI and analytics will be embedded across the care journey. An AI care navigator will guide employees from benefit activation through intake, triage and scheduling.

Tools will track benefits and treatment plans, showing coverage and expected out-of-pocket costs at each step.

AI-supported scribing will assist clinicians with documentation, and a predictor tool will estimate a patient’s likelihood of having a baby across different treatment paths.

In 2027, Kindbody plans a savings model for eligible large employers that it says will guarantee lower total fertility spend while improving clinical efficiency and patient experience.

Continue Reading

Fertility

Baby2Home app boosts new mothers’ mental health

Published

on

First-time mothers using the Baby2Home app for a year after birth reported fewer symptoms of stress, depression and anxiety than those receiving usual postpartum care.

The study found women randomised to the app reported better overall health than first-time mothers who received usual care alone.

Baby2Home is a digital tool to help new families with newborn care and staying healthy.

It offers tailored educational content, infant care trackers and mental health self-management tools, plus access to a care manager for on-demand mental health and problem-solving support.

Emily S. Miller is principal investigator and division director of maternal-fetal medicine at Women & Infants Hospital of Rhode Island.

She said: “Evidence-based digital tools like Baby2Home are opening the door to a new era of postpartum care.

“We can now extend high-quality support beyond hospital walls and into families’ everyday lives. The mental health improvements we saw underscore just how transformational that support can be.”

Researchers from Women & Infants Hospital of Rhode Island, Warren Alpert Medical School of Brown University, Northwestern University’s Feinberg School of Medicine and Lurie Children’s Hospital of Chicago ran a multi-site randomised controlled trial between November 2022 and July 2025.

The trial enrolled 642 postpartum patients, all first-time parents. For 12 months after birth, all participants received usual postpartum care; half also used the Baby2Home smartphone app.

Participants reported progress electronically at five time points over the first year. Compared with the control group, those assigned to Baby2Home reported significantly fewer symptoms of stress, depression and anxiety.

They also reported better overall health, higher relationship satisfaction with partners and family members, and greater confidence in their parenting than the control group.

Miller said: “The first year after birth is a critical period for parental mental health. Baby2Home helped new parents feel more confident, more supported and more connected.

“That translated into better health outcomes for them and their families.”

Continue Reading

Fertility

Most NHS regions in England limit IVF to single cycle, research finds

Published

on

Nearly 70 per cent of NHS regions in England fund only one IVF cycle for women under 40, breaking national guidelines, new research has found.

Twenty-nine of the 42 integrated care boards, which control local NHS budgets, now offer only one round of treatment, after four reduced access in the past year.

National Institute for Health and Care Excellence (Nice) guidelines recommend three full cycles for women under 40 who have been unable to conceive for two years.

Only two of England’s 42 integrated care boards have policies consistent with these guidelines, which they are not legally obliged to follow.

The research was conducted by the Progress Educational Trust, a fertility charity.

Sarah Norcross, the director of PET, said the impact was “devastating” for couples struggling with infertility.

She said: “Infertility is already incredibly stressful for people, and it puts them under even more pressure, because there is so much riding on whether that one NHS-funded cycle is going to work.

“And for some people, that will be their only chance, because private fertility treatment is so expensive.”

The data showed regional variations, with the whole of the north-west offering just one cycle.

“It’s a postcode lottery, and we’re seeing a race to the bottom,” said Norcross.

Of the 29 integrated care boards that offer a single cycle, 19 provide only a partial cycle, where not all viable embryos created are transferred.

There was just one recent example of improved services, from NHS South East London, which in July 2024 went from one partial to two full cycles.

The NHS estimates that about one in seven couples may have difficulty achieving a pregnancy. One cycle of IVF can cost from £5,000 at a private clinic.

Fertility rates in England and Wales have fallen since 2010 to 1.41 children per woman in 2024, the lowest on record and below the replacement level of 2.1 at which a population is stable without immigration.

Health minister Karin Smyth said in a written parliamentary answer last month that it was “unacceptable” that access to NHS-funded fertility services varied across the country.

Revised Nice fertility guidelines are due this spring, but Norcross said changing them seemed pointless.

She said: “Fertility treatment has always been a Cinderella service. It’s always been the one they’ve chosen to cut or to ignore.

“Nice has recommended three full NHS-funded cycles, for women under 40, for more than 20 years. This has never been implemented across England, unlike in Scotland.”

Norcross advocated centralised commissioning and replicating Scotland’s approach, which included financial modelling and a phased implementation starting with two cycles to avoid long waits, moving up to three once capacity was achieved.

“It is a tried and tested plan that England could follow,” Norcross added.

A Department of Health and Social Care spokesperson said: “We recognise access to fertility treatment varies across the country and we are working with the NHS to improve consistency.

“Nice provides clear clinical guidelines, and we expect integrated care boards to commission treatment in line with these.

“Updated Nice fertility guidelines are expected this spring and we will continue to support NHS England to make sure the guidance is fully considered in local commissioning decisions.”

An NHS England spokesperson said: “These clinical services are commissioned by integrated care boards for their area based on the needs of the local population and prioritisation of resources available.

“All ICBs have a responsibility to ensure services are provided fairly and are accessible by different population groups.”

Continue Reading

Trending

Copyright © 2025 Aspect Health Media Ltd. All Rights Reserved.